{"id":5732,"date":"2024-06-19T09:05:13","date_gmt":"2024-06-19T14:05:13","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5732"},"modified":"2025-06-27T11:16:41","modified_gmt":"2025-06-27T16:16:41","slug":"nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u30012024\u5e74\u30ea\u30fc\u30ea\u30f3\u30af\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba\u30fb\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u30fb\u30d7\u30e9\u30a4\u30d9\u30fc\u30c8\u30fb\u30ab\u30f3\u30d1\u30cb\u30fc\u30fb\u30b3\u30cd\u30af\u30c8\u306b\u53c2\u52a0"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2024\u5e746\u670818\u65e5<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u304a\u3088\u3073\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u5f8c\u671f\u81e8\u5e8a\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u306f\u672c\u65e5\u3001\u7d4c\u55b6\u9663\u304c2024\u5e74\u30ea\u30fc\u30ea\u30f3\u30af\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba\u30fb\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u30fb\u30d7\u30e9\u30a4\u30d9\u30fc\u30c8\u30fb\u30ab\u30f3\u30d1\u30cb\u30fc\u30fb\u30b3\u30cd\u30af\u30c8\u3067\u6295\u8cc7\u5bb6\u3068\u306e\u4e00\u5bfe\u4e00\u306e\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\u306b\u53c2\u52a0\u3059\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\u306f\u3001\u00a0<span class=\"xn-chron\">2024\u5e746\u670825\u65e5\u301c26\u65e5<\/span>.<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<\/b><\/p>\n<p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u30aa\u30d7\u30c8\u30b8\u30a7\u30cd\u30c6\u30a3\u30c3\u30af\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002\u540c\u793e\u306e\u4e3b\u529b\u88fd\u54c1\u3067\u3042\u308bMCO-010\u306f\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">\u6700\u8fd1\u767a\u8868\u3055\u308c\u305f100\u9031\u9593\u306e\u30c7\u30fc\u30bf\u306b\u3088\u308b\u3068\u3001<\/a>\u00a0\u5fa9\u5143\u30d5\u30a7\u30fc\u30ba\u00a0<span class=\"xn-money\">2b<\/span>\/3 \u7c73\u56fd\u306b\u304a\u3051\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4192527-1&h=3393632503&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D517760235%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT04945772%2525253Fterm%2525253DNanoscope%25252526draw%2525253D2%26a%3DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3002\u540c\u793e\u306f\u6700\u8fd1\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f MCO-010 \u7642\u6cd5\u306e\u7b2c 2 \u76f8 STARLIGHT \u8a66\u9a13\u3082\u5b8c\u4e86\u3057\u307e\u3057\u305f (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4192527-1&h=2980886663&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D1090222651%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT05417126%2525253Fterm%2525253Dnanoscope%25252526draw%2525253D2%25252526rank%2525253D3%26a%3DNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0MCO-010 \u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3068\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u306b\u5bfe\u3057\u3066 FDA \u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068 FDA \u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001AMD \u306b\u4f34\u3046\u5730\u56f3\u72b6\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054 MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0June 18, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on\u00a0June 25-26, 2024. About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company\u2019s lead asset, MCO-010,\u00a0recently announced the 100-week data from\u00a0the RESTORE Phase\u00a02b\/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for\u00a0retinitis pigmentosa\u00a0(NCT04945772). The company has also recently completed the Phase 2 STARLIGHT [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5733,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-19T14:05:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:16:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"wordCount\":180,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u30012024\u5e74\u30ea\u30fc\u30ea\u30f3\u30af\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba\u4e3b\u50ac\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u30fb\u30d7\u30e9\u30a4\u30d9\u30fc\u30c8\u30ab\u30f3\u30d1\u30cb\u30fc\u30fb\u30b3\u30cd\u30af\u30c8\u306b\u53c2\u52a0\u3078 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-06-19T14:05:13+00:00","article_modified_time":"2025-06-27T16:16:41+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"wordCount":180,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","url":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u30012024\u5e74\u30ea\u30fc\u30ea\u30f3\u30af\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba\u4e3b\u50ac\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u30fb\u30d7\u30e9\u30a4\u30d9\u30fc\u30c8\u30ab\u30f3\u30d1\u30cb\u30fc\u30fb\u30b3\u30cd\u30af\u30c8\u306b\u53c2\u52a0\u3078 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5732"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5732\/revisions"}],"predecessor-version":[{"id":9043,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5732\/revisions\/9043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5733"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}